Pain Control and Side Effects in Cesarean Section Anesthesia: Comparison of Intrathecal Morphine and Fentanyl
FvMinSACS
Balancing Analgesia and Side Effects: Intrathecal Fentanyl and Morphine Versus Fentanyl for Cesarean Section Anesthesia
1 other identifier
observational
180
1 country
1
Brief Summary
Intrathecal opioids are frequently combined with local anesthetics to optimize spinal anesthesia for cesarean delivery. Fentanyl, a lipophilic opioid, offers rapid onset and enhanced intraoperative analgesia. However, its postoperative analgesic duration is limited, but in contrast, morphine, a hydrophilic opioid, provides prolonged postoperative pain control but has a slower onset and a higher incidence of adverse effects, notably nausea and vomiting. This prospective, randomized, double-blind, parallel study enrolled 180 parturients scheduled for elective cesarean section, all receiving spinal anesthesia with hyperbaric bupivacaine (7.5-10 mg, adjusted to height) plus either intrathecal fentanyl 25 µg (F group) or intrathecal morphine 100 µg and fentanyl 25µg (M+F group). Primary outcomes include intraoperative and postoperative pain scores, systemic opioid consumption, and patient satisfaction, while secondary outcomes assess the incidence of opioid-related side effects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2025
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2025
CompletedFirst Submitted
Initial submission to the registry
August 14, 2025
CompletedFirst Posted
Study publicly available on registry
August 27, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2025
CompletedAugust 27, 2025
August 1, 2025
2 months
August 14, 2025
August 23, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Assessing the perioperative analgesic efficacy
Pain intensity will be evaluated using the Numeric Pain Scale, with scores obtained at the time of skin incision, at the end of surgery, and at 4h, 6h, 12h, 24h, 48h, and 72 hours postoperatively; AUE72h (sum pain intensity differences area over 72 hours) and SPID72h (time-weighted sum pain intensity differences over 72 hours). Assessments will be conducted both at rest and during mobilization. The pain scores according to the Numeric Pain Scale will be rated between 0 and 10, meaning 0 - no pain and 10 - the worst pain imaginable
6 months
Assessing the degree of patient's satisfaction
Assessing the degree of satisfaction on a five point scale with the highest rate as being "completely satisfied", followed by "satisfied", "so so", "unsatisfied" and "completely unsatisfied"
6 months
Secondary Outcomes (2)
Incidence of Additional Opioid-Related Adverse Effects
6 months
Incidence and Severity of Pruritus
6 months
Study Arms (2)
Fentanyl, Morphine and Bupivacaine
Pregnant patients scheduled for C-section that received a spinal anaesthesia mixture of Fentanyl, Morphine and Bupivacaine
Fentanyl and Bupivacaine
Pregnant patients scheduled for C-section that received a spinal anaesthesia mixture of Fentanyl and Bupivacaine
Interventions
The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.
The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.
Eligibility Criteria
The subjects of the study will be selected from the pregnant patients of Oradea Pelican Clinic Hospital.
You may qualify if:
- American Society of Anesthesiologists (ASA) physical status class I-II.
- Absence of significant past medical conditions.
- No documented hypersensitivity to any study drug.
- No history of chronic pain syndromes or regular analgesic consumption.
- No anxiety or depressive disorders diagnosis.
- Body weight ≥ 50 kg.
- Scheduled for elective cesarean delivery.
- Single fetus.
You may not qualify if:
- Patient refusal.
- Contraindication of spinal anaesthesia.
- Conversion from a natural delivery with or without an epidural anaesthesia started.
- History of substance abuse or drug dependence.
- Presence of acute or chronic fetal distress.
- Preeclampsia.
- Allergic reaction occurring after enrollment.
- Refusal to receive protocol-specified analgesics or medications.
- Requirement for surgical re-intervention within 72 hours postoperatively.
- Previous administration of opioids or other central nervous system depressants prior to intervention.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Oradealead
- Oradea Pelican Clinic Hospitalcollaborator
Study Sites (1)
University of Oradea, Pelican Clinic Hospital
Oradea, Bihor County, 410505, Romania
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Aurel Mohan, MD, PhD
Head of Surgery Department of Medicine and Pharmacy Faculty of Oradea
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 14, 2025
First Posted
August 27, 2025
Study Start
August 1, 2025
Primary Completion
October 1, 2025
Study Completion
October 1, 2025
Last Updated
August 27, 2025
Record last verified: 2025-08